Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
Current vaccines targeting surface proteins can drive antigenic variation resulting either in the emergence of more highly pathogenic viruses or of antigenically distinct viruses that escape control by vaccination and thereby persist in the host population. Influenza vaccines typically target the hi...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2013
|
_version_ | 1826259412403093504 |
---|---|
author | Boyd, A Ruiz-Hernandez, R Peroval, M Carson, C Balkissoon, D Staines, K Turner, A Hill, A Gilbert, S Butter, C |
author_facet | Boyd, A Ruiz-Hernandez, R Peroval, M Carson, C Balkissoon, D Staines, K Turner, A Hill, A Gilbert, S Butter, C |
author_sort | Boyd, A |
collection | OXFORD |
description | Current vaccines targeting surface proteins can drive antigenic variation resulting either in the emergence of more highly pathogenic viruses or of antigenically distinct viruses that escape control by vaccination and thereby persist in the host population. Influenza vaccines typically target the highly mutable surface proteins and do not provide protection against heterologous challenge. Vaccines which induce immune responses against conserved influenza epitopes may confer protection against heterologous challenge. We report here the results of vaccination with recombinant modified Vaccinia virus Ankara (MVA) and Adenovirus (Ad) expressing a fusion construct of nucleoprotein and matrix protein (NP+M1). Prime and boost vaccination regimes were trialled in different ages of chicken and were found to be safe and immunogenic. Interferon-γ (IFN-γ) ELISpot was used to assess the cellular immune response post secondary vaccination. In ovo Ad prime followed by a 4 week post hatch MVA boost was identified as the most immunogenic regime in one outbred and two inbred lines of chicken. Following vaccination, one inbred line (C15I) was challenged with low pathogenic avian influenza (LPAI) H7N7 (A/Turkey/England/1977). Birds receiving a primary vaccination with Ad-NP+M1 and a secondary vaccination with MVA-NP+M1 exhibited reduced cloacal shedding as measured by plaque assay at 7 days post infection compared with birds vaccinated with recombinant viruses containing irrelevant antigen. This preliminary indication of efficacy demonstrates proof of concept in birds; induction of T cell responses in chickens by viral vectors containing internal influenza antigens may be a productive strategy for the development of vaccines to induce heterologous protection against influenza in poultry. |
first_indexed | 2024-03-06T18:49:27Z |
format | Journal article |
id | oxford-uuid:0fb42f7b-0d62-41ce-a7c2-4ea5eb2f0c7a |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-06T18:49:27Z |
publishDate | 2013 |
record_format | dspace |
spelling | oxford-uuid:0fb42f7b-0d62-41ce-a7c2-4ea5eb2f0c7a2022-03-26T09:52:36ZTowards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0fb42f7b-0d62-41ce-a7c2-4ea5eb2f0c7aEnglishSymplectic Elements at Oxford2013Boyd, ARuiz-Hernandez, RPeroval, MCarson, CBalkissoon, DStaines, KTurner, AHill, AGilbert, SButter, CCurrent vaccines targeting surface proteins can drive antigenic variation resulting either in the emergence of more highly pathogenic viruses or of antigenically distinct viruses that escape control by vaccination and thereby persist in the host population. Influenza vaccines typically target the highly mutable surface proteins and do not provide protection against heterologous challenge. Vaccines which induce immune responses against conserved influenza epitopes may confer protection against heterologous challenge. We report here the results of vaccination with recombinant modified Vaccinia virus Ankara (MVA) and Adenovirus (Ad) expressing a fusion construct of nucleoprotein and matrix protein (NP+M1). Prime and boost vaccination regimes were trialled in different ages of chicken and were found to be safe and immunogenic. Interferon-γ (IFN-γ) ELISpot was used to assess the cellular immune response post secondary vaccination. In ovo Ad prime followed by a 4 week post hatch MVA boost was identified as the most immunogenic regime in one outbred and two inbred lines of chicken. Following vaccination, one inbred line (C15I) was challenged with low pathogenic avian influenza (LPAI) H7N7 (A/Turkey/England/1977). Birds receiving a primary vaccination with Ad-NP+M1 and a secondary vaccination with MVA-NP+M1 exhibited reduced cloacal shedding as measured by plaque assay at 7 days post infection compared with birds vaccinated with recombinant viruses containing irrelevant antigen. This preliminary indication of efficacy demonstrates proof of concept in birds; induction of T cell responses in chickens by viral vectors containing internal influenza antigens may be a productive strategy for the development of vaccines to induce heterologous protection against influenza in poultry. |
spellingShingle | Boyd, A Ruiz-Hernandez, R Peroval, M Carson, C Balkissoon, D Staines, K Turner, A Hill, A Gilbert, S Butter, C Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. |
title | Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. |
title_full | Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. |
title_fullStr | Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. |
title_full_unstemmed | Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. |
title_short | Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. |
title_sort | towards a universal vaccine for avian influenza protective efficacy of modified vaccinia virus ankara and adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
work_keys_str_mv | AT boyda towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT ruizhernandezr towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT perovalm towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT carsonc towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT balkissoond towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT stainesk towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT turnera towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT hilla towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT gilberts towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT butterc towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus |